Interoperability and data
– a platform for sharing and using diabetes data securely
ADDI Medical has been commissioned by Vinnova through the Vinter project to develop, package and manage its HOPE Databroker platform for data-driven innovation in Sweden, in an initial step as support for patients in the field of diabetes. The purpose of the platform is to create increased interoperability between systems in care and health, the academic community and the business community, i.e. to increase the ability to use data from another system or another process using standards.
The platform also enables personal and confidential data to be an active part of the digital transformation of the area. Key requirements from Vinnova here are compliance with the Swedish legislation – the Swedish Patient Data Act (PDL) and the General Data Protection Regulation (GDPR). It is addressing stimulating change in a confidential area to enable patient data to be a secure part of innovative solutions.
The requirements landscape demands the speedy delivery of a competition platform that meets all necessary technical and legal requirements for being able to process, share and reuse clinical data and health data for patients with diabetes. Based on these requirements, ADDI Medical will package and manage the HOPE Databroker over a number of years as a new modern and powerful platform for data-driven innovations in Sweden.
As early as 1 March 2021, ADDI Medical will deliver the new HOPE Databroker platform for secure sharing and use of data within the field of diabetes, with the possibility of subsequent expansion to additional diagnostic fields.
The long-term development work carried by ADDI focuses strongly on interoperability adapted to statutory requirements and regulations and generates rapid project delivery. The rapid pace of development is further made possible in combination with the broad experience in thre company from the use of HOPE Platform in healthcare.
HOPE Databroker consortium is coordinated by ADDI Medical AB in association with the Greater Stockholm Diabetes Association, Opticom International Research AB, A05 Diagnostics AB and Karolinska Institutet, among others.